1. Introduction {#sec0001}
===============

Acute Lymphoblastic Leukemia (ALL) is the most common type of childhood hematopoietic neoplasia, and is responsible for 30% of all pediatric cancers \[[@bib0001],[@bib0002]\], and is one of the principal causes of cancer deaths in children around the world [@bib0003]. The etiology of ALL is still poorly understood, although studies have shown that it may be provoked by a combination of environmental exposure and genetic susceptibility \[[@bib0004],[@bib0005]\].

Recently, a number of studies of genome-wide association (GWAS) have found single nucleotide polymorphisms (SNPs) in the *ARID5B, IKZF1, CEBPE, CDKN2A*, and *PIP4K2A* genes [@bib0006], [@bib0007], [@bib0008], [@bib0009], [@bib0010] that were related to the risk of developing ALL, specifically, the B cell lineage of the leukemia (B-cell ALL). While each of these variants is responsible for only a minor increase in the risk of developing ALL, they may have a cumulative influence on the genetic susceptibility to the disease [@bib0010]. In addition to their influence on genetic susceptibility to ALL, the prevalence of some of these variants may oscillate significantly among patients of different ancestries, which may account for ethnic differences found in the incidence of the disease [@bib0010].

In addition to the polymorphisms discovered by the GWAS, one potential genetic pathway in the development of childhood ALL is folate biosynthesis. Folate is involved in the metabolism that plays an essential role in the synthesis, repair, and methylation of the DNA. Reduced ingestion of folate during pregnancy may result in breakage of the DNA molecule, as well as a reduction in repairs and abnormal methylation, which has led to the proposal of a link between polymorphisms in the genes involved in the biosynthesis of folate and the risk of developing ALL \[[@bib0011],[@bib0012]\]. These polymorphisms may be associated with genes that codify the central regulator and the transport enzymes (for example, *MTHFD1, MTRR, MTHFR, SHMT1, GGH, SLCO1B1* and transporters of the ABC family) involved in the folate transport cycle, as well as the genes involved in the synthesis of purines, such as *AMPD1* and *ATIC* \[[@bib0011],[@bib0013],[@bib0014]\].

Most of the research that identified these genetic variants, either by GWAS or within the scope of the folate metabolism, has focused on European populations. In this case, the patterns of risk associated with these variants in highly admixed populations, such as that of the Brazilian Amazon region are completely unknown. Understanding the potential impact of these risk-associated variants is especially important in the case of variants that are substantially more frequent in non-European populations than in European ones, in order to provide important insights for the prediction of the incidence of the disease in these populations.

The present study investigated the role of 21 polymorphisms in the susceptibility to B-cell ALL in the population of the Brazilian Amazon region. These polymorphisms included five (the *ARID5B, IKZF1, CEBPE, CDKN2A*, and *PIP4K2A* genes) selected based on GWAS studies, and 16 (*MTHFD1, MTRR, MTHFR, SHMT1, GGH, SLCO1B1, ABCC1, ABCC2, ABCC3, AMPD1*, and *ATIC* genes) related to folate biosynthesis.

2. Patients and methods {#sec0002}
=======================

2.1. Ethical aspects {#sec0003}
--------------------

The present study was approved by the research committee of the Federal University of Pará (UFPA). Consent for the collection of biological samples and clinical data was obtained personally from each participant prior to the study.

2.2. Cases and controls {#sec0004}
-----------------------

The participants in the research were selected based on a case-control study approach. The case group was composed of 121 patients with B-cell ALL diagnosed at two public hospitals (the Ophir Loyola Hospital and the Octavio Lobo Childhood Cancer Hospital) in the city of Belém, Pará (Brazil) that are reference institutions for the treatment of childhood cancer in the Amazon region. The patients were diagnosed between 2006 and 2016, based on the criteria of the French-American-British (FAB) classification systems. The immunophenotyping was determined by flow cytometry [@bib0015]. The control group was composed of 155 unrelated individuals from the same socioeconomic level and geographic area as the members of the case group.

2.3. Selection of the genes and polymorphisms {#sec0005}
---------------------------------------------

The present study investigated the role of 21 polymorphisms ([Supplementary Table S1](#tbl0003){ref-type="table"}) in the susceptibility to B-cell ALL. Five of these (the *ARID5B, IKZF1, CEBPE, CDKN2A*, and *PIP4K2A* genes) were selected based on GWAS studies. The remaining 16 polymorphisms (the *MTHFD1, MTRR, MTHFR, SHMT1, GGH, SLCO1B1, ABCC1, ABCC2, ABCC3, AMPD1*, and *ATIC* genes) are related to folate biosynthesis.

2.4. Genotyping of the polymorphisms {#sec0006}
------------------------------------

The genetic material was extracted from peripheral blood samples of patients in remission, using the commercial Biopur Mini Spin Plus -- 250 extraction kit (Biopur, Brazil), based on the manufacturer\'s instructions, and quantified using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies,Wilmington, DE). The polymorphisms were genotyped using the TaqMan OpenArray Genotyping technology (Applied Biosystems, Life Technologies, Carlsbad, USA) in the QuantStudio™ 12 K Flex Real-Time PCR system (Applied Biosystems, Life Technologies, Carlsbad, USA), using the protocol published by Applied Biosystems. The Taqman Genotyper software was used to analyze the plate data and evaluate the precision of the genotype readings, as well as to control the quality of the genotyping.

2.5. RNA extraction, reverse transcriptase-polymerase chain reaction (RT-PCR) {#sec0007}
-----------------------------------------------------------------------------

Cytogenetic data regarding the defining gene fusions of the ALL subtypes: *BCR-ABL, ETV6-RUNX1, MLL-AF4, SIL-TAL* and *TCF3-PBX1* were obtained for 99 B-cell ALL patients investigated. Hyperdiploidy data were not available for most patients and were therefore not included in the study.

Venipuncture and blood collection containing anticoagulant (EDTA) from patients with ALL were performed. The blood was submitted to Ficoll Histopaque® (Sigma-Aldrich, USA) according to the manufacturer\'s protocol for lymphocyte separation. Subsequently, it was subjected to RNAeasy Mini Kit processing (Qiagen, USA) as standard protocol for total RNA extraction and cDNA conversion using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) according to manufacturer\'s instructions. For gene fusion analysis, the c-DNA obtained was used to amplify molecular targets by Polymerase Chain Reaction with the GoTaq® Colorless Master Mix kit (Promega, USA), according to the protocol instructions, using primers designed for RT-PCR multiplex reaction for fusions of interest, similar to those described by Galehdari et al. [@bib0016] with modifications.

2.6. Analysis of genetic ancestry {#sec0008}
---------------------------------

The genetic ancestry of the samples was analyzed based on the set of 61 Ancestry Informative Markers (AIMs) described by Santos et al. [@bib0017] and Ramos et al. [@bib0018]. The proportions of European, African, and Native American ancestries were estimated using STRUCTURE v2.3.3, assuming the existence of three parental populations. To infer the contribution of each parental population, additional data from Native American, Sub-Saharan, and European populations were included and further details on these populations can be found in Amador et al. [@bib0019].

2.7. Statistical analysis {#sec0009}
-------------------------

The statistical analyses were run in R v.3.4.0 (R Foundation for Statistical Computing). The first step was to verify whether each polymorphism was in Hardy-Weinberg Equilibrium (HWE). The ancestry indices were compared between samples using Mann-Whitney\'s U test. The influence of the genetic variants on susceptibility to B-cell ALL was evaluated using a Bayesian multivariate logistic regression, which included sex and genetic ancestry to control for potential confounding effects. The effect of each variant was evaluated using recessive, dominant, and log-additive models, with the model being selected based on the lowest AIC (Akaike Information Criterion) value for the association test. A Bayesian logistic regression was used to control for the effects of rare mutations. The significance of the tests was adjusted for multiple comparisons by the Bonferroni correction, with adjusted p values lower than 0.05 being considered statistically significant.

3. Results {#sec0010}
==========

3.1. Genotyping {#sec0011}
---------------

The first step in the analysis of the 21 polymorphisms was to exclude the loci with (i) allele frequencies of less than 1% (MAF≤1%), (ii) for which less than 90% of the samples were genotyped, and (iii) when the control group was not in HWE ([Supplementary Table S2](#tbl0004){ref-type="table"}). Once these criteria were applied, seven polymorphisms were left to be included in the association analysis.

3.2. Demographic characteristics of the patients {#sec0012}
------------------------------------------------

The two groups (case and control) presented distinct demographic characteristics ([Table 1](#tbl0001){ref-type="table"}). While the case group was predominantly male, the control group had a higher proportion of females. Significant differences were found between the two groups in age (*P* \< 0.001), sex (*P* = 0.001), and European (*P* = 0.001) and Amerindian ancestry (*P* = 0.001). The genetic ancestry of the case group was 45% European, 21% African, and 34% Amerindian, whereas the control group was 50% European 21% African, and 29% Amerindian ([Fig. 1](#fig0001){ref-type="fig"}). Cytogenetic data for the BCR-ABL, ETV6-RUNX1, MLL-AF4, SIL-TAL and TCF3-PBX1 fusions were available for approximately 82% of the investigated patients ([Fig. S1 Supplementary](#fig0005){ref-type="fig"}). 46.5% of the patients had none of the translocations studied. The most frequent fusion was TCF3-PBX1, followed by BCR-ABL and ETV6-RUNX1 ([Table 1](#tbl0001){ref-type="table"}).Table 1Demographic variables of the participants of the present study, by group (case or control).Table 1VariableB-cell ALLControlP-valorNumber of subjects121155Age, years[\*](#tb1fn3){ref-type="table-fn"}5.29±3.3223.77±5.48\<0.001[a](#tb1fn1){ref-type="table-fn"}Gender (Male/Female)72/4961/940.001Genetic Ancestry[\*](#tb1fn3){ref-type="table-fn"}European0.451±0.1030.507±0.1280.001[b](#tb1fn2){ref-type="table-fn"}African0.213±0.0730.209±0.0810.520[b](#tb1fn2){ref-type="table-fn"}Amerindian0.335±0.1130.284±0.1130.003[b](#tb1fn2){ref-type="table-fn"}Chromosomal translocations, n (%)99----Absent46 (46.5)----*BCR-ABL*16 (16.2)----*ETV6-RUNX1*12 (12.1)----*MLL-AF4*1 (1.0)----*TCF3-PBX1*23 (23.2)----*SIL-TAL*1 (1.0)----[^1][^2][^3]Fig. 1Box plot graph elucidates the difference between case and control groups for Amerindian, African and European ancestries in the study population.Fig. 1

3.3. Analysis of the association with susceptibility {#sec0013}
----------------------------------------------------

All seven study polymorphisms presented a significant association with susceptibility to B-cell ALL ([Table 2](#tbl0002){ref-type="table"}). In the case of the *GGH* (rs1800909, rs3758149), *CEBPE* (rs2239633), *ARID5B* (rs10821936), *MTHFR* (rs1801133), and *MTHFD1* (rs2236225) genes, the dominant or log-additive models indicated a significant protective effect in relation to the development of B-cell ALL. In the case of the *ATIC* (rs4673993) gene, the recessive model indicated a significant association with the risk of development of B-cell ALL in the study population ([Fig. 2](#fig0002){ref-type="fig"}).Table 2Distribution of the genotypes associated with susceptibility to B-cell ALL.Table 2Genotype, IDModelB-cell ALL (%)Control (%)POR (95%CI)*ARID5B\_* rs10821936Dominant\< 0.001CT+TT *vs* CC:\
0.183 (0.100--0.341)CC57 (47.5)20 (13.5)CT39 (32.5)84 (56.8)TT25 (20.0)44 (29.7)*ATIC\_* rs4673993Recessive0.004CC *vs* TC+TT:\
3.594 (1.509--8.518)TT61 (50.4)78 (51.7)TC40 (33.1)65 (43)CC20 (16.5)8 (5.3)*CEBPE\_* rs2239633Log-additive\< 0.0010.237 (0.154--0.357)GG54 (44.6)12 (7.8)GA47 (38.8)61 (39.6)AA20 (16.5)81 (52.6)*GGH\_* rs1800909Dominant\< 0.001AG+GG *vs* AA:\
0.103 (0.056--0.192)AA97 (80.8)48 (32.2)AG13 (10.8)82 (55.0)GG10 (8.3)19 (12.8)*GGH\_* rs3758149Dominant\< 0.001GA+AA *vs* GG:\
0.162 (0.085--0.303)GG58 (62.4)37 (24.2)GA11 (11.8)81 (52.9)AA24 (25.8)35 (22.9)*MTHFD1\_* rs2236225Log-additive\< 0.0010.546 (0.385--0.776)GG47 (38.8)29 (19.0)GA47 (38.8)62 (40.5)AA27 (22.3)62 (40.5)*MTHFR\_* rs1801133Log-additive\< 0.0010.399 (0.277--0.571)GG55 (45.5)29 (19.2)GA42 (34.7)61 (40.4)AA24 (19.8)61 (40.4)[^4]Supplementary Table S1Characteristics of the polymorphisms analyzed in the present study and quality control.Supplementary Table S1GeneSNP, IDAlleleFunctionChange in amino acidQuality Control*ABCC1*rs28364006A \> GMissenseThr1337AlaGenotyping failure and no HWE*ABCC2*rs717620C \> T5′ UTR--Genotyping failure*ABCC3*rs9895420T \> A5′ Flanking--No HWE*AMPD1*rs17602729G \> AStop CodonGln45TerNo HWE*ARID5B*rs10821936C \> TIntron--Accepted*ATIC*rs2372536C \> GMissenseThr116SerNo HWE*ATIC*rs4673993T \> CSplice region--Accepted*CDKN2A*rs3731217A \> CIntergenic--No HWE*CEBPE*rs2239633G \> A5′ UTR--Accepted*GGH*rs11545078G \> AMissenseThr151IleNo HWE*GGH*rs1800909A \> GMissenseCys6ArgAccepted*GGH*rs3758149G \> A5′ Flanking--Accepted*IKZF1*rs4132601T \> GUTR \'3--No HWE*MTHFD1*rs2236225G \> AMissenseArg653GlnAccepted*MTHFR*rs1801133G \> AMissenseAla222ValAccepted*MTRR*rs1801394A \> GMissenseIle22MetGenotyping failure and no HWE*PIP4K2A*rs7088318C \> AIntergenic--No HWE*SHMT1*rs1979277G \> AMissenseLeu435PheNo HWE*SLCO1B1*rs2306283A \> GMissenseAsn130AspNo HWE*SLCO1B1*rs4149015G \> A5′ Flanking--No HWE*SLCO1B1*rs4149056T \> CMissenseVal174AlaNo HWE[^5]Supplementary Material Table S2Selection criteria for the inclusion of the polymorphisms investigated in the present study.Supplementary Material Table S2GeneSNP, IDQuality Control*ABCC1*rs28364006Genotyping failure and no HWE*ABCC2*rs717620Genotyping failure*ABCC3*rs9895420No HWE*AMPD1*rs17602729No HWE*ARID5B*rs10821936Accepted*ATIC*rs2372536No HWE*ATIC*rs4673993Accepted*CDKN2A*rs3731217No HWE*CEBPE*rs2239633Accepted*GGH*rs11545078No HWE*GGH*rs1800909Accepted*GGH*rs3758149Accepted*IKZF1*rs4132601No HWE*MTHFD1*rs2236225Accepted*MTHFR*rs1801133Accepted*MTRR*rs1801394Genotyping failure and no HWE*PIP4K2A*rs7088318No HWE*SHMT1*rs1979277No HWE*SLCO1B1*rs2306283No HWE*SLCO1B1*rs4149015No HWE*SLCO1B1*rs4149056No HWEFig. 2Odds ratio of the polymorphisms investigated between case and control groups. The plot illustrates the polymorphisms odds-ratio and their 95% confidence interval by the point and line ranges, the null effect (OR = 1) is indicated by the vertical dotted line and the genetic effect model is indicated by the colors red, green and blue for dominant, log-additive and recessive models, respectively.Fig. 2

An additional analysis was performed associating the cytogenetic subtypes of B-cell ALL, according to the gene fusion investigated, with the polymorphic variants of the *ARID5B* (rs10821936) and *CEBPE* (rs2239633) genes, selected based on GWAS studies. The data are presented in [Fig. 3](#fig0003){ref-type="fig"}, [Fig. 4](#fig0004){ref-type="fig"} and in [Supplementary Table S3](#tbl0005){ref-type="table"}. The distribution of gene fusions according to the genotypes of the *ARID5B* and *CEBPE* gene variants was not statistically significant.Fig. 3Distribution of *ARID5B\_* rs10821936 gene variants according to B-ALL leukemia subtype.Fig. 3Fig. 4Distribution of *CEBPE\_* rs2239633 gene variants according to B-ALL leukemia subtype.Fig. 4Fig. 1SDistribution of cytogenetic subtypes of B-ALL for the patients investigated.Fig. 1SSupplementary Table S3Associations between genetic variants of ARID5B and CEBPE genes, and leukemia subtype of B-ALL.Supplementary Table S3Genotype, IDDistribution of cytogenetic subtypes of B-ALLP[a](#tb3S3fn1){ref-type="table-fn"}*ARID5B\_* rs10821936Absent\
*n* (%)*BCR-ABL*\
*n* (%)*ETV6-RUNX1*\
*n* (%)*MLL-AF4*\
*n* (%)*TCF3-PBX1*\
*n* (%)*SIL-TAL*\
*n* (%)*0.337*CC24 (52.2)6 (37.5)4 (33.3)1 (100)8 (34.6)0CT11 (23.9)6 (37.5)5 (41.7)012 (52.2)0TT11 (23.9)4 (25)3 (25)03 (13)1 (100)*CT+TT*22 (47.8)10 (62.5)8 (66.7)015 (65.2)1 (100)*0.425CC*24 (52.2)6 (37.5)4 (33.3)1 (100)15 (65.2)0*CEBPE\_* rs2239633*0.460*GG19 (41.3)7 (43.8)8 (66.7)09 (39.1)0GA19 (41.3)7 (43.8)3 (25)09 (39.1)1 (100)AA8 (17.4)2 (12.5)1 (8.3)1 (100)5 (21.7)0*AA+GA*27 (58.7)9 (56.3)4 (33.3)1 (100)14 (60.9)1 (100)*0.489GG*19 (41.3)7 (43.8)8 (66.7)09 (39.1)0[^6]

4. Discussion {#sec0014}
=============

Demographic factors such as sex and genetic ancestry were controlled for in the analysis of the association between the variants investigated and susceptibility for the development of B-cell ALL. The male sex and Amerindian ancestry were predominant in the case group, whereas the control group had significantly more individuals of the female sex and European ancestry, which is consistent with the findings of a previous study published by our research group [@bib0020].

Variations in the genes that regulate the folate cycle (for example, *GGH, MTHFR, MTHFD1, ATIC*) may influence susceptibility to ALL \[[@bib0011],[@bib0012]\]. The γ-glutamyl hydrolase (*GGH*) gene plays an important role in folate homeostasis, catalyzing the hydrolysis of the active polyglutamates of the natural folates into monoglutamates for the biosynthesis of nucleotides. This means that variations in the *GGH* gene may alter the amount of folate available in the cell and influence susceptibility to ALL \[[@bib0014],[@bib0021]\].

Variants of the *GGH* gene have previously been associated with altered susceptibility for ALL [@bib0013], although the present study was the first to show that the rs1800909 and rs3758149 variants of the *GGH* gene were associated with the modulation of the risk of developing B-cell ALL. Here, the homozygous genotypes of the wild variants rs1800909 and rs3758149 of the *GGH* gene were associated with a protective effect against the development of ALL in the study population (rs1800909: OR = 0.103; 95%CI = 0.056--0.192; *P* \< 0.001; rs3758149: OR = 0.162; 95%CI=0.085- 0.303; *P* \< 0.001).

Polymorphisms of the methylenotetrahydrofolate reductase (*MTHFR*) and methylenetetrahydrofolate dehydrogenase 1 (*MTHFD1*) genes are known to reduce the activity of the enzyme that is essential for folate bio-availability and metabolism \[[@bib0011],[@bib0012]\]. The rs1801133 variant of the *MTHFR* gene and the rs2236225 variant of *MTHFD1* have been widely investigated in relation to the modulation of the risk of ALL, in a number of different populations \[[@bib0012],[@bib0013],[@bib0022],[@bib0023]\]. In the present study, the log-additive association models of both genes were associated with a protective effect for the development of B-cell ALL (*MTHFR*: OR = 0.399; 95%CI = 0.277--0.571; *P* \< 0.001; *MTHFD1*: OR = 0.546; 95%CI = 0.385--0.776; *P* \< 0.001).

The *ATIC* gene codifies a bifuncional protein (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and IMP cyclohydrolase) that catalyzes the last two stages of the synthesis of Inosine monophosphate [@bib0024]. The rs4673993 variant of the *ATIC* gene has been widely shown to be associated with toxicity to treatment with methotrexate, an inhibitor of the folate pathway [@bib0025], [@bib0026], [@bib0027]. The present study represents the first report of the role of the rs4673993 variant of the *ATIC* gene as a risk factor for ALL. The homozygous mutant genotype of the rs4673993 variant of the *ATIC* gene was associated with a 360% increase in the risk of developing ALL in the study population (OR = 3.594; 95%CI = 1.509--8.518; *P* = 0.004).

A number of GWAS studies have found an over-representation of polymorphisms of the *ARID5B* and *CEBPE* genes in ALL patients in comparison with individuals that do not have the disease \[[@bib0006], [@bib0007], [@bib0008],[@bib0010]\]. The *ARID5B* gene plays a fundamental role in the regulation of the development of the embryo, and cell growth and differentiation through the repression of the expression of specific differentiation genes. Deficiencies in the expression of the *ARID5B* gene in the developing fetus may interrupt the maturation of the B lymphocytes and contribute to leukemogenesis \[[@bib0028],[@bib0029]\]. The rs10821936 variant of the *ARID5B* gene has been associated with susceptibility to ALL in children in a number of different populations \[[@bib0007],[@bib0006],[@bib0010],[@bib0030],[@bib0031]\]. In the present study, however, the homozygous genotype of the wild rs10821936 variant was associated with a protective effect for the development of B-cell ALL (OR = 0.183; 95%CI = 0.100--0.341; *P* \< 0.001).

The CCAAT ligation/potentializing proteins (CEBPs) are transcription factors involved in the development of hematopoietic cells, including granulopoiesis [@bib0032]. A number of studies \[[@bib0007],[@bib0008],[@bib0030],[@bib0033],[@bib0034],[@bib0035]\] have demonstrated a strong association between the rs2239633 variant of the *CEBPE* gene and susceptibility to childhood ALL. In the present study, the log-additive model of the rs2239633 variant of the *CEBPE* gene indicated a protective effect against the development of B-cell ALL (OR = 0.237; 95%CI = 0.154--0.357; *P* \< 0.001).

Variants of the GWAS-identified *ARID5B* and *CEBPE* genes are reported in the literature associated with certain ALL subtypes. For example the variant rs10821936 of the *ARID5B* gene is strongly associated with hyperdiploid B-ALL and MLL-germline. And the rs2239633 variant of the *CEBPE* gene is largely null in children with and without MLL rearrangements. Most of these association studies were performed in poorly mixed populations [@bib0036]. Furthermore, the association between ALL cytogenetic subtypes and ethnic variation is poorly verified in the literature. In order to better explore the relationship of variants identified in GWAS studies with ALL cytogenetic subtypes in the population of the Brazilian Amazon region, we performed an additional analysis comparing the *BCR-ABL, ETV6-RUNX1, MLL-AF4, SIL-TAL* and *TCF3-PBX1* gene fusions with the variants of the *ARID5B* and *CEBPE* genes studied. Most patients did not present any of the investigated translocations. The distribution of gene fusions according to the *ARID5B* and *CEBPE* gene polymorphism genotypes was not statistically significant.

5. Conclusion {#sec0015}
=============

The results of the present study indicate that the variants of the genes *GGH* (rs1800909, rs3758149), *MTHFR* (rs1801133), *MTHFD1* (rs2236225), *ATIC* (rs4673993), *ARID5B* (rs10821936), and *CEBPE* (rs2239633) play a fundamental role in the risk of developing B-cell ALL in the study population. This is the first study to describe the influence of these variants in the development of B-cell ALL in the population of the Brazilian Amazon region.
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[^1]: Significance determined by Student\'s *t*-test.

[^2]: Significance determined by Mann-Whitney test.

[^3]: Mean (±Standard Deviation).

[^4]: OR: odds ratio; CI: confidential interval. P: Logistic regression adjusted for sex and genetic ancestry.

[^5]: 3UTR: 3′UTR regulation; 5UTR: 5′UTR regulation.

[^6]: Significance determined by Fisher exact test.
